SPOTLIGHT: NIH researcher cited for misconduct

The NIH has concluded that senior researcher Dr. Thomas Walsh engaged in "serious misconduct" by failing to report more than $100,000 in outside income from unauthorized and unreported contracts with drug companies. A probe found that he accepted money from 25 companies, some of which owned the drugs he was studying. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.